NATERA INC (Common Stock) – ticker 45E (NTRA)
NASDAQ
Closed
Aug 24, 2026
Day's Range
321.5952 wk Range
157.43Overview - NTRA - NATERA INC (Common Stock) – ticker 45E
Key Statistics
Valuation
Enterprise Value
47.00B
P/E (Trailing)
‪-215.11‬
P/E (Forward)
‪-3,722.30‬
PEG Ratio
‪5.89‬
Price / Sales (TTM)
‪17.67‬
Price / Book
‪26.71‬
EV / EBITDA
‪-209.46‬
Profitability
Gross Margin
‪64.45%‬
Profit Margin
‪-7.10%‬
Operating Margin
‪-10.29%‬
Return on Assets
‪-8.07%‬
Return on Equity
‪-12.54%‬
Ownership
Shares Outstanding
143.61M
Float
139.92M
Short % of Shares Outstanding
‪3.12%‬
Held by Insiders
‪2.85%‬
Held by Institutions
‪96.57%‬
Price stats
Beta
‪1.51‬
50-Day Avg
‪272.65‬
200-Day Avg
‪229.33‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
22 analysts
Average price target
‪$ 336.74‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NTRA - NATERA INC (Common Stock) – ticker 45E
Peers - NTRA - NATERA INC (Common Stock) – ticker 45E
Peer Comparison
Compared with companies in Diagnostics & Research listed on NASDAQ.
- NTRANASDAQNATERA INC (Common Stock) – ticker 45E47.86BMarket Cap+50.33%52-week change-215.11P/E (Trailing)‪-7.10%‬Profit Margin
- IDXXNASDAQIDEXX Laboratories, Inc.43.87BMarket Cap-15.16%52-week change39.06P/E (Trailing)‪25.03%‬Profit Margin
- ILMNNASDAQIllumina, Inc.33.12BMarket Cap+54.58%52-week change41.01P/E (Trailing)‪18.33%‬Profit Margin
- GHNASDAQGuardant Health Inc.22.90BMarket Cap+63.75%52-week change-51.42P/E (Trailing)‪-38.32%‬Profit Margin
- MEDPNASDAQMedpace Holdings Inc.17.32BMarket Cap+24.80%52-week change35.96P/E (Trailing)‪17.66%‬Profit Margin
- ICICLRNASDAQICON plc13.28BMarket Cap+0.02%52-week change264.97P/E (Trailing)‪0.32%‬Profit Margin
- RDNTNASDAQRadNet Inc.6.04BMarket Cap+9.41%52-week change1425.75P/E (Trailing)‪-0.93%‬Profit Margin
Profile Summary - NTRA - NATERA INC (Common Stock) – ticker 45E
About
Natera Inc. is a diagnostics company specializing in advanced genetic testing services for patients, clinicians, and healthcare systems. The company focuses on analyzing cell-free DNA to support clinical decision-making across several key areas of medicine. Natera’s portfolio includes non-invasive prenatal tests that…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
